Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

N/ANo Longer AvailableNCT03564964

Suven Life Sciences Limited

Overview

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.

Study Type

EXPANDED_ACCESS

Conditions

Alzheimer Disease Dementia Cognition Disorders

Interventions

SUVN-502DRUG

Tablet

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who have completed the 30 week treatment period of study CTP2S1502HT6 as planned and wish to continue treatment with SUVN-502. * Subject (or subject's legally acceptable representative) and caregiver must sign the Informed Consent Form (ICF) to participate in the study. Exclusion Criteria: * Has participated or is participating in any other clinical (investigational) study after completion of CTP2S1502HT6 study. * Is treated or likely to require treatment during the study with any medication prohibited by this expanded access program.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.